Fractyl Health Seeks Shareholder Approval for Reverse Split to Avoid Nasdaq Delisting
GUTS sits 80% above its 52-week low of $0.377.
Summary
Fractyl Health is seeking shareholder approval for a reverse stock split to regain Nasdaq compliance and avoid delisting. The special meeting is scheduled for September 24, 2026.
Key Events · Corporate Governance and Compliance · GUTS
-
Reverse Split Proposal
The board is seeking approval to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15, with the exact ratio to be determined by the board.
-
Nasdaq Delisting Risk
The company has not regained compliance with the $1.00 minimum bid price requirement and expects a delisting notice after September 9, 2026.
-
Share Count Impact
At a 1-for-15 split, outstanding shares would drop from 158,648,963 to 10,576,597, while authorized shares remain at 300,000,000, increasing available unissued shares.
-
Special Meeting Date
Stockholders will vote on the proposal at a virtual special meeting on September 24, 2026.
Analysis · GUTS · Industrial Applications And Services
To lift its share price above Nasdaq's $1.00 minimum bid requirement, Fractyl Health is asking shareholders to approve a reverse stock split of up to 1-for-15. The company has not regained compliance and expects a delisting notice after September 9, 2026. If approved, the split would reduce outstanding shares from 158.6 million to as low as 10.6 million, while authorized shares remain at 300 million, giving the board significant room to issue new shares. The vote is set for September 24, 2026.
At the time of this filing, GUTS was trading at $0.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $108.2M. The 52-week trading range was $0.38 to $2.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.